Latest "Mifepristone Cushing Syndrome" News Stories

11:36 EDT 17th September 2014 | BioPortfolio

Here are the most relevant search results for "Mifepristone Cushing Syndrome" found in our extensive news archives from over 250 global news sources.

More Information about Mifepristone Cushing Syndrome on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Mifepristone Cushing Syndrome for you to read. Along with our medical data and news we also list Mifepristone Cushing Syndrome Clinical Trials, which are updated daily. BioPortfolio also has a large database of Mifepristone Cushing Syndrome Companies for you to search.

Showing "Mifepristone Cushing Syndrome" News Articles 1–25 of 2,300+

Extremely Relevant

Response in Cushing's Syndrome Treated With Mifepristone

What are strong drivers of response to mifepristone therapy in patients with Cushing disease? Clinical Endocrinology

NormoCort Could Become Leading Cushing’s Syndrome Drug, Says GlobalData

Cortendo’s NormoCort has the potential to become the front-line medical therapy for cushing’s syndrome (CS), but only if its commercial strategy adapts to a growing market

Cortendo Enrolls First Patient into Cushing’s Study

Cortendo AB announced that the first patient has been enrolled into the Phase 3 SONICS trial, i.e., “Study of NormoCort in Cushing’s Syndrome.” The patient was enrolled by one of the trial’s lead principal investigators at a Pituitary Center from a prestigious institution in Baltimore, Maryland.


Neuroendocrine cancer: An activating hotspot mutation in PRKACA provides clues for adrenal Cushing syndrome therapeutics

Serotonin transporter is a mifepristone pharmacological target

(Neural Regeneration Research) Results show that mifepristone attenuates serotonin transporter activity by directly inhibiting the serotonin transporter, and suggests that the serotonin transporter is a pharmacological target of mifepristone for the ...

Corcept shares halved on mifepristone failure in depression

Corcept Therapeutics saw its stock price cut in half after the company revealed in its first quarter earnings report that mifepristone failed to achieve the primary endpoint in a Phase III clinical trial for the treatment of psychotic depression.

Cushing disease: Often a victim of mistaken identity

The symptoms of Cushing disease are unmistakable to those who suffer from it -- excessive weight gain, acne, distinct colored stretch marks on the abdomen, thighs and armpits, and a lump, or fat deposit, on the back of the neck. Yet the disorder ofte...

Corcept Therapeutics to Announce First Quarter Financial Results and Corporate Update and Host Conference Call

MENLO PARK, CA -- (Marketwired) -- 04/30/14 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 7, 2014. The Company will also host a conference call that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). Conference Call Information To participate, dial 1-888-771-4371 from the United State...

Corcept falls on 1Q14 financial results, trial discontinuation

Corcept Therapeutics Inc. (NASDAQ:CORT) fell $2.03 (50%) to $1.99 on Wednesday after the company reported 1Q14 financial results that missed the Street and disclosed that it discontinued the Phase III Study 14 of mifepristone to treat psychotic depre...

Patients with Cushing’s syndrome experience significant weight loss while taking oral medication

Sinai Hospital of Baltimore endocrinologist, Henry G. Fein, M.D., today presented new research showing that patients with Cushing's syndrome, a rare disease that can lead to extreme weight gain, type 2 diabetes, high blood pressure and psychological ...

New Research on Corcept's Korlym(R) for Patients With Cushing's Syndrome to Be Presented at ICE/ENDO 2014

CHICAGO, IL -- (Marketwired) -- 06/19/14 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders, today announced that new clinical research on Korlym® (mifepristone) will be presented at the joint meeting of the International Socie...

Cortendo enrols first patient in Phase 3 SONICS trial

Cortendo has announced that the first patient has been enrolled into the Phase 3 SONICS trial, i.e., “Study Of NormoCort In Cushing’s Syndrome."

/ CORRECTION - Corcept Therapeutics

CHICAGO, IL -- (Marketwired) -- 06/20/14 -- In the news release, "New Research on Corcept's Korlym® for Patients With Cushing's Syndrome to Be Presented at ICE/ENDO 2014," issued Thursday, June 19, 2014 by Corcept Therapeutics (NASDAQ: CORT), we are advised by the company that the session schedule has now been updated to reflect accurate presentation times with poster numbers added. Complete cor...

Mifepristone: Phase I started

Mifepristone: Phase III discontinued

Genetics: Pinpointing a hotspot in adrenal Cushing syndrome

A gain-of-function point mutation in the gene that encodes one of the catalytic subunits of protein kinase A (PRKACA) in cortisol-producing adrenocortical adenomas has been independently reported by three groups. This hotspot point mutation (c.617T>G...

Rett Syndrome Association of MA joins to explore treatment option

(International Rett Syndrome Foundation) Rett Syndrome Association of Massachusetts and are thrilled to announce today their renewed commitment to work together to defeat Rett syndrome. A generous $150,000 donation from RSAM will sup...

Rheumatoid arthritis and metabolic syndrome

Rheumatoid arthritis (RA) and metabolic syndrome share several pathologic characteristics, such as changes in body composition, lipid levels and insulin sensitivity, that may increase cardiovascular mortality. Here, Kerekes and co-authors discuss ass...

Basketball Star's Career Cut Short by Diagnosis of Marfan's Syndrome

Individuals with Marfan's Syndrome (see: Marfan syndrome) are often very tall so I have wondered whether some basketball players have this genetic disorder. A recent article cited a specific instance of this (see: Baylor star Isaiah Austin's NBA pros...

Link between Down syndrome, leukemia uncovered

A connection between people with Down syndrome and having a heightened risk of developing acute lymphoblastic leukemia during childhood has been uncovered by researchers. "For 80 years, it hasn't been clear why children with Down syndrome face a shar...

Down syndrome: Behind the scenes of genetics, leukemia

A group of geneticists have focused for many years on the genetic characteristics of Down syndrome. They have sequenced the exome, a specific part of our genome, in a cohort of patients affected both by Down Syndrome and acute lymphoblastic leukaemia...

Heartbeat Client Korlym Named Brand of the Year by Pharmaceutical Executive

Pharmaceutical Executive magazine has selected Corcept Therapeutics’ Korlym® as the 2014 Brand of the Year. For the first time, the publication has recognized two brands in two distinct categories – one in the treatment of chronic disease and one in the treatment of orphan status rare disease. Teva Pharmaceutical’s Copaxone® was the Brand of the Ye...

Obesity: Cerebral damage in obesity-associated metabolic syndrome

The prevalence of the metabolic syndrome has increased in tandem with that of obesity. The metabolic syndrome is associated with structural and functional cerebral damage. A new study confirms the association between the metabolic syndrome and reduce...

GIST With Nephrotic Syndrome as a Paraneoplastic Syndrome

This unusual case documents a patient with GIST of the stomach who presented with refractory nephrotic syndrome. Journal of Medical Case Reports

RSAM, renew commitment to defeat Rett syndrome

Rett Syndrome Association of Massachusetts and are thrilled to announce today their renewed commitment to work together to defeat Rett syndrome. A generous $150,000 donation from RSAM will support a approved grant to...

Search BioPortfolio:

News Quicklinks